Mirabegron, a beta3-adrenoceptor agonist, is currently under investigation as an alternative strategy to achieve weight loss by inducing browning of subcutaneous white adipose tissue and increasing energy expenditure
[DOI] [PubMed] [Google Scholar] Dobric I, Drvis P, Petrovic I, et al
Their use has expanded from the originally-developed purpose, with studies highlighting their potential for a variety of uses beyond metabolic control, including: moderation or reduction of substance use and addictive disorders to those with type 2 diabetes neuroprotective benefits individualised management of polycystic ovary syndrome playing a role in the pain management of persistent Despite their prohibitively expensive cost if purchased via private healthcare, their use appears to already be disrupting the food industry
doi: 10.1002/mpr.329 39 WhiteIRRoystonPWoodAM
Well-designed randomized clinical studies are needed to systematically evaluate the evidence for the use of these hepatoprotective agents as treatment options for APAP-induced liver injury, to determine the timing of initiation of the therapy, and to further define the optimal treatment regimen
Regulators have a word for it: doping
